

Stylianos T Panopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4177023/publications.pdf>

Version: 2024-02-01

40
papers

833
citations

430754

18
h-index

526166

27
g-index

40
all docs

40
docs citations

40
times ranked

1280
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac Tissue Characterization and the Diagnostic Value of Cardiovascular Magnetic Resonance in Systemic Connective Tissue Diseases. <i>Arthritis Care and Research</i> , 2014, 66, 104-112.	1.5	66
2	Biological treatments and connective tissue disease associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, 362-367.	1.2	60
3	Low disease activity“irrespective of serologic status at baseline“associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	1.6	59
4	Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study. <i>Lung</i> , 2013, 191, 483-489.	1.4	55
5	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1013-1016.	0.5	43
6	The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 195.	1.6	42
7	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e60-e60.	0.5	41
8	Beneficial effect of the 5-HT _{1A} receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study. <i>United European Gastroenterology Journal</i> , 2015, 3, 266-271.	1.6	37
9	Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. <i>Autoimmunity Reviews</i> , 2018, 17, 816-820.	2.5	34
10	Cardiovascular magnetic resonance imaging in asymptomatic patients with connective tissue disease and recent onset left bundle branch block. <i>International Journal of Cardiology</i> , 2014, 171, 82-87.	0.8	28
11	Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value. <i>Diagnostics</i> , 2019, 9, 220.	1.3	28
12	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 31-39.	1.5	28
13	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097697.	1.2	26
14	Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 2380-2385.	2.9	25
15	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 267.	1.6	24
16	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	0.9	24
17	Update on assessment and management of primary cardiac involvement in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 53-65.	1.0	23
18	Clinical and financial burden of active lupus in Greece: a nationwide study. <i>Lupus</i> , 2016, 25, 1385-1394.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. <i>RMD Open</i> , 2022, 8, e002279.	1.8	18
20	Intact Calibers of Retinal Vessels in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 608-613.	1.0	16
21	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 895-902.	1.5	15
22	Is Vasculopathy Associated with Systemic Sclerosis More Severe in Men?. <i>Journal of Rheumatology</i> , 2013, 40, 46-51.	1.0	14
23	Pseudo-infarction pattern in diffuse systemic sclerosis. Evaluation using cardiovascular magnetic resonance. <i>International Journal of Cardiology</i> , 2016, 214, 465-468.	0.8	14
24	Diffuse, subendocardial vasculitis. A new entity identified by cardiovascular magnetic resonance and its clinical implications. <i>International Journal of Cardiology</i> , 2013, 168, 2971-2972.	0.8	13
25	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 56.	1.6	12
26	Psoriasis as an adverse reaction to biologic agents beyond anti-TNF- α therapy. <i>European Journal of Dermatology</i> , 2021, 31, 307-317.	0.3	12
27	Autochthonous <i>Plasmodium vivax</i> malaria in a Greek schoolgirl of the Attica region. <i>Malaria Journal</i> , 2012, 11, 52.	0.8	11
28	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 288.	0.3	9
29	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. <i>RMD Open</i> , 2020, 6, e001303.	1.8	8
30	Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Diagnostics</i> , 2020, 10, 49.	1.3	7
31	Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience. <i>Journal of Rheumatology</i> , 2022, 49, 68-73.	1.0	6
32	Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study. <i>Rheumatology International</i> , 2022, 42, 303-309.	1.5	5
33	Severe oesophageal disease and its associations with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 82-85.	0.4	5
34	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 29-33.	0.4	2
35	Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
36	The True Association of Systemic Sclerosis with Myasthenia Gravis and the Myth of D-Penicillamine-Induced Myasthenia. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, e1-e3.	1.0	0

#	ARTICLE	IF	CITATIONS
37	FRI0313â€¦DIFFERENTIAL PERFORMANCE OF NAILFOLD VIDEO CAPILLAROSCOPIC PARAMETERES IN THE DIAGNOSIS AND PROGNOSIS OF SYSTEMIC SCLEROSIS. , 2019, , .		0
38	Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 57-62.	0.4	0
39	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 29-39.	0.4	0
40	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 29-33.	0.4	0